Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT01729260 · ClinicalTrials.gov registry record · Phase 1
Mebendazole in Newly Diagnosed High-Grade Glioma Patients Receiving Temozolomide
A Phase 1 study of Newly Diagnosed High-Grade Glioma, sponsored by Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins.
- Completed
- Registry status
- Phase 1
- Development phase
- 24
- Enrollment target
- 1
- Study location
NCT01729260 is a Phase 1 study of Newly Diagnosed High-Grade Glioma that has completed, run by Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins. The registered enrollment target is 24 participants. The trial reports 1 study location across 1 state.
The verdict
NCT01729260, a Phase 1 study of Newly Diagnosed High-Grade Glioma, has completed, sponsored by Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins.
- COMPLETED
- Registry status
- Phase 1
- Development phase
- 24 participants
- Enrollment target
- 1
- Study location
Study Summary
The purpose of this study is to find the highest dose of mebendazole (MBZ) that can be safely given to people with malignant brain tumors in combination with the current standard of care (temozolomide) without causing severe side effects. We also want to find out if MBZ can slow the growth of the brain tumor. The study doctors have found that MBZ is effective against malignant brain tumors in the laboratory and animal models of brain tumors.
Conditions Studied
Interventions
- DRUG Mebendazole
Study Locations (1)
Maryland
- The Johs Hopkins Hospital - Baltimore
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 24 participants |
| Start Date | 2013-04-04 |
| Est. Completion | 2021-04-16 |
| Phase | Phase 1 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT01729260
The ClinicalTrials.gov registry entry for NCT01729260 describes a study currently listed as completed, categorized as Phase 1. The registered enrollment target is 24 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins, which has 523 total studies on file at ClinicalTrials.gov.
The record links to 1 condition, with Newly Diagnosed High-Grade Glioma appearing as the primary indexed condition, and to 1 intervention - of which Mebendazole is the first listed.
NCT01729260 reports 1 study location spanning 1 distinct geographic area - top geographies include Maryland.
Frequently Asked Questions
What is clinical trial NCT01729260 about?
NCT01729260 is a clinical study titled "Mebendazole in Newly Diagnosed High-Grade Glioma Patients Receiving Temozolomide". The purpose of this study is to find the highest dose of mebendazole (MBZ) that can be safely given to people with malignant brain tumors in combination with the current standard of care (temozolomide) without causing severe side effects. We also want to find out if MBZ can slow the growth of the br...
What is the current status of trial NCT01729260?
This trial is currently completed. It is a Phase 1 study. The enrollment target is 24 participants. The study started on 2013-04-04. Estimated completion is 2021-04-16.
What conditions does trial NCT01729260 study?
This clinical trial studies the following conditions: Newly Diagnosed High-Grade Glioma.
What interventions are being tested in trial NCT01729260?
The interventions under investigation include: Mebendazole (DRUG).
Who is sponsoring clinical trial NCT01729260?
This trial is sponsored by Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins, which has 523 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT01729260 being conducted?
This trial has 1 study location across Maryland. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.